Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LYN101

Phase 1Small molecule

SShanghai TTM-Bio Technology Co., Ltd

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoporotic FractureActive, not recruiting

Osteoporotic FracturePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Osteoporotic Fracture

NCT07178327

Clinical

Trials by Indication[1]

Osteoporotic Fracture1 trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Administration of LYN101 in Healthy Subjects and Multiple Administrations in Postmenopausal Women With Low Bone Mass

Active, not recruiting·SShanghai TTM-Bio Technology Co., Ltd·Phase 1·NCT07178327·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LYN101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LYN101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LYN101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai TTM-Bio Technology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai TTM-Bio Technology Co., Ltd

Related News